Screener
Corcept Therapeutics CORT Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $14,910 | $40,444 |
| Accrued research and development expenses | 21,628 | 33,954 |
| Accrued and other liabilities | 115,347 | 90,603 |
| Short-term operating lease liability | 1,917 | 1,084 |
| Total current liabilities | 153,802 | 166,085 |
| Long-term operating lease liability | 7,504 | 5,023 |
| Long-term accrued government rebates | 6,132 | 2,562 |
| Long-term accrued income taxes | 15,488 | 15,176 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's operating lease liabilities (current)?
- Corcept Therapeutics (CORT) reported operating lease liabilities (current) of $1.92M in Q2 2026.
- How has Corcept Therapeutics's operating lease liabilities (current) changed year-over-year?
- Corcept Therapeutics's operating lease liabilities (current) increased by 88.5% year-over-year, from $1.02M to $1.92M.
- What is the long-term trend for Corcept Therapeutics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Corcept Therapeutics's operating lease liabilities (current) has grown at a -12.0% compound annual growth rate (CAGR), from $2.05M to $1.08M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Corcept Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude